Photodynamic therapy (PDT) has emerged as an attractive alternative in cancer therapy, but therapeutic effects suffer from low photosensitizing efficiency and poor retention of photosensitizes in cancer cells. This paper reports the photosensitizers which show absorption and emission in the long-wavelength region and high photosensitizing efficiency can be formed in situ in cells from 4,6-dibromothieno[3,4-b]thiophene derivative (TT-5-P) after white light irradiation. The self-oligomerization of TT-5-P is uptaken in cells upon light irradiation-induced cell apoptosis simultaneously and efficiently. In addition, the formation of oligomers (TT-5-Ps) enhances the retention time in cells remarkably, which is advantageous for boosting the photodynamic therapy efficiency. Moreover, the selectivity toward tumor cells of TT-5-P can be improved obviously via the formation of complex of TT-5-P with albumin. This in situ photoinduced self-oligomerization strategy can be utilized to design effective biomaterials for long-term imaging and improved therapy.

中文翻译：

---

含有三苯基鏻基团的 4,6-二溴噻吩并[3,4-b]噻吩化合物光诱导自低聚在细胞中产生高效光敏剂

光动力疗法 (PDT) 已成为癌症治疗中有吸引力的替代方案，但治疗效果受到光敏效率低和光敏剂在癌细胞中的保留差的影响。本文报道了在长波长区域显示吸收和发射的光敏剂，可以在细胞中原位形成4,6-二溴噻吩[3,4- b白光照射后的]噻吩衍生物（TT-5-P）。TT-5-P 的自寡聚化在光照射诱导的细胞凋亡时同时有效地被细胞吸收。此外，低聚物（TT-5-Ps）的形成显着提高了在细胞中的停留时间，有利于提高光动力治疗效率。此外，TT-5-P与白蛋白形成复合物可明显提高TT-5-P对肿瘤细胞的选择性。这种原位光诱导自寡聚化策略可用于设计用于长期成像和改进治疗的有效生物材料。